Effectiveness and Safety of Acupuncture for Obesity and Over-weight People

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02108236

Enrollment

110

Registered

2014-04-09

Start date

2014-05-31

Completion date

Unknown

Last updated

2015-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Keywords

acupuncture, chinese traditional medicine

Brief summary

To determine the efficacy and safety of acupuncture for obesity and overweight people in China.

Interventions

DEVICEacupuncture

Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* The individuals is phlegm-dampness constitution and female. * Age is between 18 and 45 years. * BMI is between 24 and 50. * The individuals voluntarily sign the informed consent form. * The individuals live in Harbin City of China.

Exclusion criteria

* Secondary obesity, eg:pituitary diseases, hypothalamic disorder, hypothyroidism, pancreatic diseases，hyperadrenocorticism, postmenopausal obesity etc. * The individuals with server cardiovascular and cerebrovascular diseases and cancer. * Having therapy for obesity in the last three months. * The individuals do not adhere to the treatment or are with other treatments. * Female individuals with pregnancy, lactation and planning a pregnancy in the two months. * Critical patients or patients combined with liver and kidney damage. * Individuals with visual and auditory memory disorders or psychosis.

Design outcomes

Primary

Measure	Time frame
body mass index(BMI)	2 month after treatment

Secondary

Measure	Time frame
Blood sugar	2 month after treatment
Total cholesterol	2 month after treatment
waist-to-hip ratio (WHR)	2 month after treatment
High-density lipoprotein cholesterol	2 month after treatment
Low-density lipoprotein cholesterol	2 month after treatment
Triglycerides	2 month after treatment

Countries

China

Contacts

Primary ContactXie Ning, PhD

xiening2014@163.com086 045182111401

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026